Loading...
XASX
ZLD
Market cap3mUSD
Jul 22, Last price  
0.41AUD
1D
-2.38%
1Q
17.14%
Jan 2017
-93.99%
IPO
-99.86%
Name

Zelira Therapeutics Ltd

Chart & Performance

D1W1MN
P/E
P/S
51.37
EPS
Div Yield, %
Shrs. gr., 5y
21.34%
Rev. gr., 5y
-34.19%
Revenues
95k
-68.47%
569,479140,69121,079,1580034,25000000300,000100,042313,757769,0300663,3161,540,624301,12194,952
Net income
-37m
L+556.18%
-311,668-901,336-38,161,91612,614,569-20,270,809-1,687,9937,025-637,958-311,843-290,217-400,080-898,637-6,157,415-1,729,806-3,567,802-7,015,045-8,549,079-11,945,303-5,573,007-36,568,904
CFO
-4m
L-39.46%
-2,563,859-7,088,027-14,809,640-2,211,296-1,571,261-1,182,623101,925-572,818-259,894-276,254-292,893-331,818-2,201,066-2,624,947-3,344,223-6,936,276-8,616,594-9,427,224-7,249,078-4,388,590
Earnings
Aug 26, 2025

Profile

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialisation of cannabinoid-based medicines for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company also provides OTC products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as ITURA, an advanced relief cream formula that targets multi-symptoms, such as numbness and tingling, muscle cramps, insensitivities, and pain associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; and the Children's Hospital of Philadelphia. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.
IPO date
Jul 28, 2003
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
95
-68.47%
301
-80.45%
Cost of revenue
4,260
10,572
Unusual Expense (Income)
NOPBT
(4,165)
(10,271)
NOPBT Margin
Operating Taxes
(920)
(1,143)
Tax Rate
NOPAT
(3,245)
(9,128)
Net income
(36,569)
556.18%
(5,573)
-53.35%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,770
BB yield
-11.64%
Debt
Debt current
3,686
143
Long-term debt
2,559
591
Deferred revenue
Other long-term liabilities
Net debt
5,615
544
Cash flow
Cash from operating activities
(4,389)
(7,249)
CAPEX
Cash from investing activities
920
2,829
Cash from financing activities
3,924
1,770
FCF
(3,192)
(8,005)
Balance
Cash
586
146
Long term investments
43
43
Excess cash
625
175
Stockholders' equity
(4,173)
31,712
Invested Capital
5,949
32,118
ROIC
ROCE
EV
Common stock shares outstanding
11,347
10,068
Price
0.28
-81.46%
1.51
55.67%
Market cap
3,177
-79.10%
15,203
94.88%
EV
9,134
15,656
EBITDA
(4,165)
(9,725)
EV/EBITDA
Interest
739
77
Interest/NOPBT